DKRT Investments Corp. Makes New Investment in Novo Nordisk A/S $NVO

DKRT Investments Corp. acquired a new stake in Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 25,000 shares of the company’s stock, valued at approximately $1,387,000. Novo Nordisk A/S makes up approximately 0.3% of DKRT Investments Corp.’s portfolio, making the stock its 29th biggest holding.

A number of other large investors also recently modified their holdings of NVO. Martin Capital Partners LLC boosted its holdings in Novo Nordisk A/S by 53.8% during the third quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock worth $6,524,000 after buying an additional 41,129 shares during the last quarter. Smith Chas P & Associates PA Cpas increased its stake in shares of Novo Nordisk A/S by 105.3% in the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock valued at $22,497,000 after acquiring an additional 207,959 shares during the last quarter. Clifford Swan Investment Counsel LLC raised its position in shares of Novo Nordisk A/S by 13.7% in the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after acquiring an additional 37,453 shares during the period. Markel Group Inc. raised its position in shares of Novo Nordisk A/S by 4.9% in the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after acquiring an additional 110,061 shares during the period. Finally, Cantor Fitzgerald Investment Advisors L.P. bought a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $1,294,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $38.60 on Friday. The firm has a market cap of $172.35 billion, a P/E ratio of 11.12 and a beta of 0.73. Novo Nordisk A/S has a twelve month low of $35.85 and a twelve month high of $88.55. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm’s 50 day moving average price is $51.41 and its two-hundred day moving average price is $52.38.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 23.63%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Nordea Equity Research lowered shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. TD Cowen restated a “buy” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 3rd. Finally, Citigroup began coverage on Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a “neutral” rating on the stock. Five research analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $53.93.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley raised Novo Nordisk to Equal Weight, and related analyst chatter lifted the stock in earlier trading — a near-term supportive catalyst. Novo Nordisk A/S (NYSE:NVO) Raised to Equal Weight at Morgan Stanley
• Neutral Sentiment: General coverage and “trending” write-ups (Zacks/Yahoo) are driving retail attention but contain no new fundamental news; these pieces can increase volume/volatility without changing long‑term fundamentals. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Be aware of ticker-noise: several press releases referencing “NVO” (Novo Resources, ASX: NVO) circulated today — these are not related to Novo Nordisk (NYSE:NVO) but can create confusion in scanners and newsfeeds. Completion of Tranche 1 of Placement and Valuation Update
• Negative Sentiment: Roche reported positive Phase II results for petrelintide (up to ~10.7% weight loss with good tolerability) and plans further development — new obesity competitors gaining efficacy/tolerability could pressure Novo Nordisk’s market share and growth expectations. Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
• Negative Sentiment: A study reporting generic Ozempic/Wegovy could be produced for under $3/month highlights potential long‑term pricing pressure and margin risk if cheaper biosimilars/generics scale globally. That raises erosion risk to high-margin GLP‑1 revenues. Generic Ozempic Could Cost Less Than $3 a Month, Study Shows
• Negative Sentiment: Regulatory scrutiny increased after the FDA issued (another) warning about marketing/ads for Ozempic/Wegovy — ongoing ad/regulatory issues could hurt promotion and patient uptake and lead to fines or stricter controls. FDA sends Novo Nordisk 2nd warning over GLP-1 ads
• Negative Sentiment: Pomerantz law firm announced an investigation into Novo Nordisk investor claims, which can increase legal uncertainty and weigh on sentiment until resolved. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.